Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effects of EDP-235 in Non-hospitalized Adults With Mild or Moderate COVID-19
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs EDP-235 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Acronyms SPRINT
- Sponsors Enanta Pharmaceuticals
- 17 Apr 2024 According to Enanta Pharmaceuticals media release, data from the study has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27-30 in Barcelona, Spain.
- 08 May 2023 According to Enanta Pharmaceuticals media release, full data from SPRINT will be presented at a future medical meeting or in a peer-reviewed publication.
- 08 May 2023 Results published in the Enanta Pharmaceuticals Media Release